


ISCT Conference Program

Sunday April 21, 2013

4:00pm – 7:00pm **REGISTRATION**

Auckland Promenade

Monday April 22, 2013

 Coffee and tea will be available prior to the start of the first morning sessions

7:00am – 7:00pm **REGISTRATION**

Auckland Promenade

8:00am – 5:30pm Global Regulatory Perspectives Workshop

New Zealand 1, 2

9:00am – 4:30pm Flow Cytometry Workshop

Offsite at the Maurice Wilkins Centre

8:00am – 5:00pm FACT Training Workshop
Marlborough 2

FACT Training Breakout Session
Marlborough 3

5:00pm – 7:00pm Corporate Symposium **Miltenyi Biotec** (Refer to Corporate Guide for Details)

New Zealand 3, 4


7:00pm – 7:30pm Welcome Address

New Zealand 1, 2

7:30pm – 9:30pm Welcome Reception

Auckland Room

Tuesday April 23, 2013

 Coffee and tea will be available prior to the start of the first morning sessions

7:00am – 4:00pm **REGISTRATION**

Auckland Promenade

7:30am – 8:30am

STRATEGIES FOR COMMERCIALIZATION TRACK 1 Cell Characterization for Commercialization of Cell Therapies

New Zealand 1, 2

CO-CHAIRS: STEVE OH (SG) AND GUY MOENECLAËY (AU)

SPEAKERS:

Mark Bonyhadi (US) – Leveraging new approaches for cell therapy product characterization: Identity, Purity and Safety Testing

Jyoti Arora (AU) – In vivo characterisation of cellular therapy products for commercialisation using medical imaging

Ming Hao Zheng (AU) – Process characterization of autologous somatic cellular product: the 10 year R&D experiences

7:30am – 8:30am

QUALITY AND OPERATIONS TRACK 1 Immunotherapy Technical Topics

Marlborough 1, 2, 3

CHAIR: RUSSELL CRUZ (US)

SPEAKERS:

Kenneth Micklethwaite (AU) – Muscle CAR Maintenance – Quality systems and CAR T-cells

Janice Fogarty (AU) – Mesenchymal Stromal Cell Therapy

7:30am – 8:30am

STRATEGIES FOR COMMERCIALIZATION TRACK 2 By the way, Who's Paying for All of This?


New Zealand 3, 4

CHAIR: DAWN DRISCOLL (AU)

SPEAKERS:

Richard Maziarz (US) – Perspectives on cell therapy reimbursement from the front lines of medicine

Jim Butler (AU) – The HTA imperative: Key issues in securing reimbursement



Tuesday April 23, 2013 *continued*

8:45am – 9:00am **OPENING REMARKS** by Kurt Gunter New Zealand 1, 2

9:00am – 10:30am

PLENARY SESSION 1 – PRESIDENTIAL PLENARY PLURIPOTENT STEM CELLS New Zealand 1, 2

CHAIR: KURT GUNTER (US)

SPEAKERS:

- David Ma (AU)** – Reprogramming somatic cells to the pluripotent state for use in cellular therapy
- Mahendra Rao (US)** – Manufacturing stem cell derivatives for screening and therapy
- Alan Davidson (NZ)** – Modelling cystinosis with induced pluripotent stem cells

10:30am – 11:00am **COFFEE BREAK WITH EXHIBITS** Auckland Room

11:00am – 12:15pm

ORAL ABSTRACT PRESENTATIONS 1 Epsom 1, 2, 3

Mesenchymal Stem Cells

CHAIR: LUC SENSEBÉ (FR)

PRESENTERS:

- Allan Dietz (US)** – Data in support of the clinical use of adipose derived MSC: growth, storage, function and safety
- Caroline Gargett (AU)** – A tissue engineering construct comprising human endometrial mesenchymal stromal cells and polyamide/gelatin mesh evaluated in a preclinical animal model of pelvic organ prolapse repair
- Sze Chin (MY)** – Intra articular injection of autologous bone marrow-derived mesenchymal stromal cells in patients with moderate to severe osteoarthritis
- Steve Oh (SG)** – Extracellular matrix free microcarrier cultures of human pluripotent stem cells induced by inhibition of rock-myosin II signaling

11:00am – 12:15pm

ORAL ABSTRACT PRESENTATIONS 2 New Zealand 1, 2

Hematopoietic Stem Cells

CHAIR: EJ SHPALL (US)

PRESENTERS:

- Marc Turner (UK)** – Progress towards the cGMP production of pluripotent stem cell derived red blood cells
- Alla Dolnikov (AU)** – GSK-3 β inhibition promotes T cell reconstitution and preserves naïve T cell phenotype in mice transplanted with human haematopoietic stem cells.
- Ian McNiece (US)** – Bone marrow versus PBPC for allogeneic stem cell transplant: defining the optimal graft
- Russell Cruz (US)** – Infusion of CD19-directed/multivirus specific-cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation for B cell malignancies
- Amit Khot (AU)** – Low dose lenalidomide induction followed by autologous transplantation in untreated patients with myeloma is associated with adequate collection of haematopoietic and dendritic cell precursors and high response rates

11:00am – 12:15pm

ORAL ABSTRACT PRESENTATIONS 3 Marlborough 1, 2, 3

Quality and Operations

CO-CHAIRS: DOMINIC WALL (AU) AND THOMAS LEEHUIS (US)

PRESENTERS:

- Robert Nordon (AU)** – Mapping and modelling ex vivo cell culture processes directly from cell tracking data
- Patricia Distler (US)** – Revisions to ISBT 128 nomenclature for cellular therapy
- Mariele Viganò (IT)** – Analytical procedures validation for good manufacturing practice (GMP) production of mesenchymal stem cells from different sources
- Chih Wei (UK)** – Regulatory blind spots in cellular therapy translation experience from Australia
- Marc Turner (UK)** – Establishment of a bank of blood donor derived Epstein Barr virus specific T cell lines for treatment of post-transplant lymphoproliferative disease.

Tuesday April 23, 2013 *continued*

11:00am – 12:15pm	<p>STRATEGIES FOR COMMERCIALIZATION TRACK 3 New Zealand 3, 4</p> <p>Risk in Cell Therapy Commercialization</p> <p>CHAIR: CHRISTOPHER BRAVERY (UK)</p> <p>SPEAKERS:</p> <p>Ronnda Bartel (US) – Commercial strategies for ixmyelocel-T, a novel autologous therapy for severe, chronic cardiovascular disease</p> <p>Miles Prince (AU) – Assessing Risk in Cell Therapy Clinical Trials</p> <p>Lucy Foley (UK) – Considerations for the Widespread Adoption of Limbal Stem Cell Transplantation</p>
-------------------	--

12:15pm – 1:45pm LUNCH WITH EXHIBITS Auckland Room

12:30pm – 1:30pm	<p>Corporate Tutorial GE Healthcare <i>(Refer to Corporate Guide for Details)</i> New Zealand 3, 4</p>	<p>Corporate Tutorial BioLife Solutions <i>(Refer to Corporate Guide for Details)</i> New Zealand 1, 2</p>	<p>Corporate Tutorial Corning Life Sciences <i>(Refer to Corporate Guide for Details)</i> Epsom 1, 2, 3</p>
------------------	---	---	--

1:45pm – 3:15pm	<p>PLENARY SESSION 2 – NOVEL APPROACHES USING MSCs New Zealand 1, 2</p> <p>CHAIR: EJ SHPALL (US)</p> <p>SPEAKERS:</p> <p>EJ Shpall (US) – Mesenchymal stem cells to enhance cord blood engraftment</p> <p>Edwin Horwitz (US) – MSCs for Bone Regeneration: It's not what you think!</p> <p>Paul Simmons (AU) – Mesenchymal Precursor Cells (MPC): A platform technology for multiple therapeutic applications</p>
-----------------	--

1:45pm – 3:15pm	<p>QUALITY AND OPERATIONS TRACK 2 Marlborough 1, 2, 3</p> <p>Process Development</p> <p>CHAIR: SHIRLEY BARTIDO (US)</p> <p>SPEAKERS:</p> <p>Julie Allickson (US) – Considerations for Tissue Engineering & Regenerative Medicine Product Development Prior to Clinical Trials</p> <p>Allan Dietz (US) – Organizing the IND: Templates and Processes to Speed IND Preparation</p> <p>Xiuyan Wang (US) – Large-Scale Clinical-Grade Retroviral Vector Production In iCELLis Nano Bioreactor</p>
-----------------	---

3:15pm – 3:30pm COFFEE BREAK WITH EXHIBITS Auckland Room

3:30pm – 5:00pm	<p>WORKSHOP 1 Epsom 1, 2, 3</p> <p>Tumor Vaccines and Beyond</p> <p>CHAIR: JOHN BARRETT (US)</p> <p>SPEAKERS:</p> <p>Jonathan Serody (US) – Using Autologous Stem Cell Transplantation as a Platform for Building Tumor Vaccination</p> <p>J H Frederik Falkenburg (NL) – Benefit and Risk of targeting HLA Class-II in the treatment of hematological malignancies</p> <p>John Barrett (US) – Prevention of leukemic relapse after allogeneic stem cell transplantation with leukemia-specific T cells</p>
-----------------	---

3:30pm – 5:00pm	<p>WORKSHOP 2 New Zealand 1, 2</p> <p>Hot Topics in Haplo and Cord Transplant</p> <p>CHAIR: CATHERINE BOLLARD (US)</p> <p>SPEAKERS:</p> <p>Xiao-Jun Huang (CN) – Improving outcomes after Haploidentical SCT</p> <p>Satoshi Takahashi (JP) – Strategies to improve the cord blood engraftment – a Japanese perspective</p> <p>Patrick Hanley (US) – Improving immune reconstitution after cord blood and haploidentical SCT</p>
-----------------	---

Wednesday April 24, 2013 *continued*

7:30am – 8:30am

QUALITY AND OPERATIONS TRACK 4

Sharing Paperwork that Actually Works

CHAIR AND FACILITATOR: MARTIN HILDEBRANDT (DE)

Marlborough 1, 2, 3

8:45am – 10:15am

PLENARY SESSION 3 – T CELL IMMUNOTHERAPY

CHAIR: HELEN HESLOP (US)

SPEAKERS:

- Stan Riddell (US) – *Design of chimeric receptors and composition of T cell products for adoptive therapy*
- Carl June (US) – *Engineered T cells for cancer therapy*
- Malcolm Brenner (US) – *Will Cellular Immunotherapies for Cancer Ever Become Standard of Care?*

New Zealand 1, 2

8:45am – 10:15am

QUALITY AND OPERATIONS TRACK 5

Cellular Therapy Product Testing

CHAIR: ANNETTE TRICKETT (AU)

SPEAKERS:

- Pamela Clark (AU) – *Optimised Microbial Screening for HPC*
- Christopher Tsai (TW) – *Stem Cell Testing: Meeting the needs of clinical applications*
- Elaine Coustan-Smith (SG) – *Flow Cytometry methods for product testing in NK cell therapy trials*

Marlborough 1, 2, 3

10:15am – 10:45am

COFFEE BREAK WITH EXHIBITS

Auckland Room

10:45am – 12:15pm

ORAL ABSTRACT PRESENTATIONS 4

Immunotherapy and Dendritic Cells

CHAIR: STEPHAN MIELKE (DE)

PRESENTERS:

- Inge Jedema (NL) – *Hematopoiesis-specific T-cells may contribute to GVHD reactivity by induction of collateral damage to non-hematopoietic tissues during an ongoing profound gvl reaction*
- Chrystal Louis (US) – *A phase II study of carboplatin and docetaxel followed by Epstein-Barr virus specific cytotoxic T lymphocytes for refractory/relapsed EBV-positive nasopharyngeal carcinoma*
- Hermann Bohnenkamp (DE) – *Automated in vitro generation of tri-virus-specific CD4+ and CD8+ T-lymphocytes for adoptive immunotherapy*
- Patrick Hanley (US) – *Naïve t-cell-derived CTL recognize atypical epitopes of CMVPP65 with higher avidity than CMV-seropositive donor-derived CTL – a basis for treatment of post-transplant viral infection by adoptive transfer of T-cells from virus-naïve donors*
- Chun Ma (AU) – *Prophylactic infusion of multi-virus specific T cells for management of viral reactivation and infection in patients post allogeneic hematopoietic stem cell transplantation (HSCT)*
- Minhtran Ngo (US) – *An antigen presenting complex for the generation of broad-specificity effector T lymphocytes for the treatment of EBV-associated malignancies*

New Zealand 1, 2

10:45am – 12:15pm

ORAL ABSTRACT PRESENTATIONS 5

Regenerative Medicine and Translational Process Development

CO-CHAIRS: ROBERT DEANS (US) AND OHAD KARNIELI (IL)

PRESENTERS:

- Kong Then (UK) – *Autologous cultivated oral mucosal epithelial cells transplantation (COMET) with amniotic membrane based sheets for severe ocular chemical injury*
- Sue Ngein Leow (MY) – *Subretinal transplantation with human umbilical cord-derived mesenchymal stem cells delays retinal degeneration in royal college of surgeons rats*
- Jaroslav Michalek (CZ) – *Stem cell therapy of osteoarthritis using stromal vascular fraction cells*
- Audrey Varin (FR) – *The CD200/CD200R axis: new control mechanism of bone remodeling*
- Inge Jedema (NL) – *Production of leukemia-reactive T-cells via a good manufacturing practice procedure for treatment of patients with acute or chronic B-cell malignancies after allogeneic stem cell transplantation*

Epsom 1, 2, 3

10:45am – 12:15pm

STRATEGIES FOR COMMERCIALIZATION TRACK 6

Clinical Themes Across Commercialization: Cord Blood Expansion Products

CO-CHAIRS: ROBERT NORDON (AU) AND CLAUDIA ZYLBERBERG (US)

SPEAKERS:

- Shelly Heimfeld (US) – *Frozen, pre-expanded cord blood as an off-the-shelf universal blood stem cell source*
- Ian McNiece (US) – *The Role of Academia in Development of Cellular Therapy Products*
- Lynnet Koh (US) – *Improving Stem Cell Software: Targeting Selectins for Homing and Engraftment of Cells in Regenerative Medicine*

New Zealand 3, 4



10:45am – 12:15pm	QUALITY AND OPERATIONS TRACK 6 Roundtable Debate: Pros and Cons in the Cellular Therapy Field CHAIR: LYNN O'DONNELL (US)	Marlborough 1, 2, 3
12:15pm – 1:45pm LUNCH WITH EXHIBITS Auckland Room		
12:30pm – 1:30pm ANNUAL GENERAL MEETING New Zealand 1, 2		
12:30pm – 1:30pm	Corporate Tutorial kSep Systems (Refer to Corporate Guide for Details)	Epsom 1, 2, 3
1:45pm – 3:15pm	PLENARY SESSION 4 – COMMERCIAL PROGRESS IN REGENERATIVE MEDICINE New Zealand 1, 2	
	CHAIR: DAWN DRISCOLL (US) SPEAKERS: Timothy Allsopp (US) – Commercial development of regenerative medicines: trials & tribulations Evan Snyder (US) – The rational use of cell-based therapies – viewpoint from a scientist who advises regulatory agencies Sharron Gargosky (US) – Orchestrating Autologous Dendritic Cell Therapy Clinical Trials Across 15 Countries	
1:45pm – 3:15pm	QUALITY AND OPERATIONS TRACK 7 Marlborough 1, 2, 3	
	Challenging Quality Situations CHAIR: LIZABETH CARDWELL (US) PANELISTS: Cheryl Hutchins (AU), Vicki Antonenas (AU), Dhana Gounder (NZ), Martin Bleasdale (AU), Massimo Dominici (IT)	
3:15pm – 3:30pm COFFEE BREAK WITH EXHIBITS Auckland Room		
3:30pm – 5:00pm	WORKSHOP 3 Epsom 1, 2, 3	
	Regenerative Medicine for Cardiac and Neurological Disease CHAIR: JANET MACPHERSON (AU) SPEAKERS: James Chong (AU) – Cardiac Regeneration Using Cell Therapy Chris Bredeson (CA) – Autologous Hematopoietic Stem Cell Transplantation as a Paradigm for Immune Repair and Reinduction of Immune Tolerance – A Clinician's Perspective Bronwen Connor (NZ) – Regenerating the Brain	
	WORKSHOP 4 New Zealand 1, 2	
	Immune Therapy for GVHD CHAIR: GEOFF HILL (AU) SPEAKERS: Geoff Hill (AU) – Cytokine modulation in transplantation: Mouse and man John Koreth (US) – Regulatory T cell homeostasis in GVHD – Role of Interleukin-2	
3:30pm – 5:00pm	STRATEGIES FOR COMMERCIALIZATION TRACK 7 New Zealand 3, 4	
	Approval and Post-Approval Experience CHAIR: ANTONIO LEE (KR) SPEAKERS: Douglas Arm (US) – Autologous Cell Therapy at the Point-Of-Care: Building a Global Business Chul-Won Ha (KR) – CARTISTEM(R) – World's First Allogeneic Stem Cell Drug for OA: Clinical Results and Post-Approval Status Update Anish S. Majumdar (IN) – An open label, multicentric, dose-ranging Phase II clinical study for evaluating the safety and efficacy of pooled allogeneic bone marrow-derived mesenchymal stem cells for treating patients with critical limb ischemia due to Buerger's disease	
3:30pm – 5:00pm	QUALITY AND OPERATIONS TRACK 8 Marlborough 1, 2, 3	
	Disaster Planning and Recovery CHAIR: SUSY KIRWAN (NZ) SPEAKERS: Cheryl Hutchins (AU) – Disaster Planning in a Cellular Therapy Facility – Experiences from the 2011 Brisbane Flood Hemant Patel (NZ) – The Christchurch Experience John Miller (US) – Medical Response to Marrow Toxic Injury Events: The Radiation Injury Treatment Network (RITN)	

Wednesday April 24, 2013 *continued*

5:00pm – 6:00pm

MASTER CLASS 3
How to Run a Large GMP Facility

Marlborough 1, 2, 3

CHAIR: ADRIAN GEE (US)

SPEAKERS:

- Adrian Gee (US) – GMP Manufacturing in Texas – where Bigger is Expected to be Better
- Bruce Levine (US) – Design and Operation of Two Cell Processing Sites Within the Hospital of the University of Pennsylvania, or “Gentrification by Technology”
- Dominic Wall (AU) – Good governance for good manufacturing – commercial and regulatory challenges

5:00pm – 6:30pm


Poster Session 2

New Zealand Foyer

7:00pm – midnight

GALA – LOCATION: AUCKLAND WAR MEMORIAL MUSEUM

Thursday April 25, 2013

 Coffee and tea will be available prior to the start of the first morning sessions

7:00am – 3:00pm

REGISTRATION

Auckland Promenade

7:30am – 8:30am

TECHNICAL SESSION 2

Epsom 1, 2, 3

NK Cells

CHAIR: KATY REZVANI (US)

SPEAKERS:

- Katy Rezvani (US) – Ex vivo expanded cord blood Natural Killer cells as a novel therapeutic for lymphoid malignancies
- Dario Campana (SG) – NK cell therapy of cancer

7:30am – 8:30am

TECHNICAL SESSION 3

New Zealand 1, 2

Novel Cell Expansion Technologies

CHAIR: RAEWYN BROADY (CA)

SPEAKERS:

- David DiGiusto (US) – In vitro expansion and in vivo evaluation of adult hematopoietic stem and progenitor cells
- Juan Vera (US) – Optimized Manufacture of CAR-T Cells for Clinical Applications
- Megan Levings (CA) – Expanding and tracking human regulatory T cells

7:30am – 8:30am

STRATEGIES FOR COMMERCIALIZATION TRACK 8

New Zealand 3, 4

Downstream Logistics of Commercial Cell Products

CHAIR: SHIRLEY BARTIDO (US)

SPEAKERS:

- Kim Raineri (SG) – Packaging and Delivery of Cell Therapy Products by a CMO
- Liz Cardwell (US) – Stability and Traceability of Cellular Therapy Products during Shipment
- Morey Kraus (US) – Roadmap to Clinical Utility for Newborn Stem Cell Products

7:30am – 8:30am

QUALITY AND OPERATIONS TRACK 9

Marlborough 1, 2, 3

BEACON Cell Therapy Bioprocessing Tools and Reagents Database

CHAIR: LYNN O'DONNELL (US)

SPEAKERS:

- Brian Poole (CA) – The Tools & Reagents Database – Past, Present and Future
- Michelle Keir (AU) – A User's Perspective

8:45am – 10:15am

PLENARY SESSION 5 – ISCT-ASBMT JOINT SESSION: VIRUS SPECIFIC T CELLS *New Zealand 1, 2*

CHAIR: DAVID GOTTLIEB (AU)

SPEAKERS:

- David Gottlieb (AU) – Rebuilding immunity to prevent infection after stem cell transplant
- Ann Leen (US) – Extending the range and applicability of antigen specific T cells for viral infection
- Richard O'Reilly (US) – The potential and limitations of HLA non-identical transplant donor and third party donor derived virus-specific T-cells in stem cell and organ transplantation



Thursday April 25, 2013 *continued*

8:45am – 10:15am	QUALITY AND OPERATIONS TRACK 10 Cryobiology, Cryopreservation and Post-Thaw Process CHAIR: PING LAW (SG) SPEAKERS: Jason Acker (CA) – Cryobiology 101: The response of cell-based therapeutics to cryopreservation Zbigniew M. Szczepiorkowski (US) – Cryopreservation – when the function really matters... Shelly Heimfeld (US) – Cell Therapy Cryopreservation: Issues and Challenges with Stability Assessment and Post-thaw Processing	Marlborough 1, 2, 3
10:15am – 10:45am COFFEE BREAK WITH EXHIBITS Auckland Room		
10:45am – 11:45am	ORAL ABSTRACT PRESENTATIONS 6 Nervous System Repair/Cardiovascular Regeneration PRESENTERS: Matthias Klugmann (AU) – AAV-based gene therapy approaches for the treatment of canavan disease Hossein Bahavarand (IR) – Transplantation of anterior-specified neural progenitors derived from human induced pluripotent stem cell improves the repair of the crushed optic nerve Nasser Aghdami (IR) – Phase III randomized clinical trial comparing the effects of autologous bone marrow derived MNC and CD133 cells transplantation in ami patients during cabg Kelly Ledford (US) – Potential atheroprotective effects of ixmyelocel-T cellular therapy	Epsom 1, 2, 3
10:45am – 11:45am	ORAL ABSTRACT PRESENTATIONS 7 Gene Therapy CHAIR: JOHN RASKO (AU) PRESENTERS: Bruce Levine (US) – Adoptive transfer of gene-modified T-cells engineered to express high-affinity TCR's for cancer-testis antigens NY-ESO-1 or LAGE-1, in multiple myeloma (MM) patients post autologous hematopoietic stem cell transplant (ASCT) Saar Gill (US) – Effective targeting of primary human acute myeloid leukemia using ANTI-CD123 chimeric antigen receptor engineered T cells Amit Khot (AU) – Autologous peripheral blood T lymphocytes transduced with an anti Lewisy chimeric receptor gene can be infused safely and persist in patients with Lewisy positive acute myeloid leukaemia Gunnar Kvalheim (NO) – Clinical experiences with therapeutic DC vaccines targeting autologous cancer stem cells in glioblastoma	New Zealand 3, 4
10:45am – 11:45am	QUALITY AND OPERATIONS TRACK 11 Worldwide Surveys on T-Cells and MSCs CHAIR: SHANNON EAKER (US) MODERATOR/PRESENTER: KNUT NISS (US) Shannon Eaker (US) – ISCT T-cell Global Survey Results: Questionnaire to Identify Standard Methods in Reporting T-cell Cultures and Identification Knut Niss (US) – The ISCT Survey on MSC Production Methods: a Global View PANELISTS: Bruce Levine (US), David DiGiusto (US), Austin Wang (TW), Jennifer Ho (TW)	Marlborough 1, 2, 3
10:45am – 12:15pm	REGULATIONS AROUND THE WORLD SESSION 1 SPEAKERS: Glenn Smith (TGA, Australia) – Regulation of Cell Therapies in Australia Stewart Jessamine (MedSafe, New Zealand) – New Zealand's regulatory framework for cells and tissues Lee Lee Ong (Health Sciences Authority, Singapore) – Regulation of human cell- and tissue-based therapeutic products Tetsuya Kusakabe (Pharmaceuticals and Medical Devices Agency, Japan) – Regulatory updates on Cellular and Tissue-based products in Japan	New Zealand 1, 2
11:45am – 1:15pm LUNCH WITH EXHIBITS Auckland Room		
12:00pm – 1:00pm	Corporate Tutorial Elsevier (Cytotherapy) <i>(Refer to Corporate Guide for Details)</i> New Zealand 3, 4	Corporate Tutorial Charter Medical <i>(Refer to Corporate Guide for Details)</i> Epsom 1, 2, 3

Thursday April 25, 2013 *continued*

1:15pm – 2:45pm	<p>WORKSHOP 5 Epsom 1, 2, 3 GI Disorders CHAIR: SARAH YOUNG (NZ) SPEAKERS: Hootie Warren (US) – <i>Dissecting and exploiting the autologous immune response to colorectal cancer</i> Sarah Young (NZ) – <i>Identification and activation of CD4 T cells from patients with colorectal cancer and Crohn's disease</i> Marian Sturm (AU) – <i>Allogeneic Mesenchymal Stromal Cell Treatment for Biologic Refractory Crohn's Disease</i></p> <p>WORKSHOP 6 New Zealand 3, 4 Cell Therapies for Solid Tumors CHAIR: RAJIV KHANNA (AU) SPEAKERS: Michael Kershaw (AU) – <i>Genetic redirection of T cells against the Lewis-Y tumor associated antigen</i> Steve Grupp (US) – <i>Adapting successful CAR therapy to solid tumors - can we move beyond CD19</i> Rajiv Khanna (AU) – <i>Cellular immunotherapy for infectious complications and human malignancies: A new paradigm in personalized medicine</i></p>
1:15pm – 2:45pm	<p>QUALITY AND OPERATIONS TRACK 12 Marlborough 1, 2, 3 Daily Technical Challenges Encountered by Cellular Therapy Laboratories: "When a good day turns bad... now what am I supposed to do?" CHAIR: LIZETTE CABALLERO (US) Panelists: Lizette Caballero (US), Vicki Antonenas (AU), Thomas Leemhuis (US)</p>
1:15pm – 2:45pm	<p>REGULATIONS AROUND THE WORLD SESSION 2 New Zealand 1, 2 SPEAKERS: Younjoo Park (Korea FDA) – <i>Korea Regulatory Framework on Cell Therapy Products</i> Yi-Chu Lin (Taiwan FDA) – <i>Regulatory Development of Cell Therapy Products in Taiwan</i> Paula Salmikangas (Finnish Medicines Agency) – <i>Development and authorization of cell-based therapies in Europe</i> Liz Anne Gillham-Eisen (Health Canada) – <i>The Regulation of Cellular Therapies in Canada</i> Kimberly Benton (US FDA) – <i>US FDA Regulatory Framework for Cell Therapy Products</i></p>
2:45pm – 2:55pm	<p>BEST POSTER AND ORAL ABSTRACT AWARDS PRESENTATION & EXHIBITOR PASSPORT WINNERS ANNOUNCEMENTS New Zealand 1, 2 <i>(Refer to Corporate Guide)</i></p>
2:55pm – 4:25pm	<p>PLENARY SESSION 6 – GENE THERAPY New Zealand 1, 2 CHAIR: PETER BROWETT (AU) SPEAKERS: Steve Wilton (AU) – <i>Therapeutic alternative splicing as a customized genetic therapy: hope and hype</i> Gwendolyn Binder-Scholl (US) – <i>TCR Engineered T Cell Therapy for Oncology</i> Matt During (US) – <i>Gene therapy, after years in the nursery is it finally of age?</i></p>
2:55pm – 4:25pm	<p>QUALITY AND OPERATIONS TRACK 13 Marlborough 1, 2, 3 Small GMP Facility Management CHAIR: PING LAW (SG) SPEAKERS: Lynn O'Donnell (US) – <i>2013: A Space Odyssey – Quest for More or Making the Most of What You Have</i> Ping Law (SG) – <i>Who Is the Manager of a Small Facility: an Expert in Technology, Business or Regulatory Affairs?</i></p>